THANKTIVA THANKTASTIC ANKTIVA
LIVE

Serial Number

98456624

Owner

ImmunityBio, Inc.

Attorney

Alicia M. Passerin

Filing Date

Mar 19, 2024

Add to watchlist:

No watchlists yet
View on USPTO

THANKTIVA THANKTASTIC ANKTIVA Trademark

Serial Number: 98456624

THANKTIVA THANKTASTIC ANKTIVA is a trademark filed by ImmunityBio, Inc. on March 19, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

ImmunityBio, Inc. (8 trademarks)

3530 John Hopkins Court
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

March 19, 2024

Registration Date

Not Registered

Published for Opposition

May 6, 2025

Goods & Services

Medical services; medical information; providing a website featuring medical information in the fields of pharmaceuticals, immunotherapy, immuno-oncology, cancer, autoimmune diseases, and infectious diseases; providing medical information relating to pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases

Pharmaceutical preparations and substances for the treatment of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical preparations and substances for the prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; biological preparations for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases and infectious diseases in the fields of immunotherapy and immuno-oncology; anti-infectives for medical use for the treatment and prevention of immunologic dysfunction, autoimmune diseases and infectious diseases

Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 26, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jun 25, 2026 EX2G
SOU EXTENSION 2 FILED
Jun 25, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 25, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2025 EXRA
SOU EXTENSION 1 GRANTED
Dec 11, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 11, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 11, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 1, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 6, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 6, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 30, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 2, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 1, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 1, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 1, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Dec 30, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 30, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 3, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 3, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 3, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 26, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2024 NWOS
NEW APPLICATION ENTERED
Mar 19, 2024 NWAP